ADPT — Adaptive Biotechnologies Corporation

Summary of Adaptive Biotechnologies Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $70.9 million, a 45% increase year-over-year.
• MRD Revenue: $67.1 million, up 53% year-over-year, contributing approximately 95% of total revenue.
• Immune Medicine Revenue: $3.8 million, down 26% year-over-year.
• Sequencing Gross Margin: 70%, an increase from 62% a year ago.
• Adjusted EBITDA: Loss of $2.5 million, with MRD segment showing adjusted EBITDA of $12.1 million (compared to a loss of $4.1 million in Q1 2025).
• Net Loss: $20 million, including $2.9 million in interest expense.

2. Strategic Updates and Business Highlights

• MRD Growth: Significant growth in clinical volumes, with clonoSEQ tests reaching a record of nearly 32,600, up 41% year-over-year.
• Community Testing: Community volumes grew 67% year-over-year, now representing 35% of total testing.
• Biopharma Business: Revenue grew 53% year-over-year, with a backlog of approximately $254 million, up 24%.
• Regulatory Milestones: Recognized first primary endpoint milestone in the CEPHEUS trial for multiple myeloma.
• EMR Integration: Continued progress with six new Epic accounts added year-to-date, enhancing operational efficiencies.

3. Forward Guidance and Outlook

• MRD Revenue Guidance: Raised to $260 million - $270 million for the full year, up from $255 million - $265 million.
• Volume Growth Expectations: Anticipating at least 35% growth in clinical volumes for 2026.
• Operational Efficiency: On track to achieve over 70% sequencing gross margins and positive adjusted EBITDA by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• Immune Medicine Revenue Decline: A significant drop of 26% year-over-year, attributed to timing of sample receipts and processing.
• Cash Burn: Although cash burn was reduced, the company ended the quarter with approximately $222 million in cash, which could raise concerns about long-term sustainability.
• Regulatory Risks: Potential changes in reimbursement structures and government policies could impact revenue, particularly regarding Medicare and PAMA reporting requirements.
• Competitive Pressures: The market for MRD testing is becoming increasingly competitive, which could affect market share and pricing.

5. Notable Q&A Insights

• Community Testing Conversations: Transition in discussions from "what is MRD?" to practical implementation, indicating growing acceptance in clinical practices.
• Reimbursement Stability: clonoSEQ is not currently subject to PAMA reporting requirements, providing some reassurance regarding reimbursement stability.
• Pharma Partnerships: Ongoing discussions with biopharma partners about expanding MRD adoption, particularly in community settings.
• Future of Primary Endpoints: The potential for MRD to be used as a companion diagnostic is being explored, which could enhance its market position.
• Sales Strategy: Current sales force of 65 is deemed sufficient for the year, with a focus on optimizing existing accounts rather than significant expansion.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, providing a balanced view of Adaptive Biotechnologies' current position and outlook.